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Purpose or Objective: The risk of colorectal adenomas 
(CRAs) in childhood cancer survivors (CCS) is unknown. In the 
general population and in individuals with cancer 
susceptibility syndromes, CRAs are associated with colorectal 
carcinoma (CRC) risk and this knowledge is the basis for 
colorectal cancer screening. To support recommendations for 
or against CRC screening among asymptomatic CCS, we aim 
to estimate the risk of histologically confirmed CRAs in a 
large cohort of 5-year CCS and to quantify the contribution of 
associated treatment-related factors. 
 
Material and Methods: The Dutch Childhood Oncology Group-
Late Effects After Childhood Cancer (DCOG LATER) cohort 
includes 6,168 five-year CCS treated between 1/1/1963 and 
12/31/2001 in one of the seven Dutch pediatric 
oncology/hematology centers before age 18. Detailed 
information on prior cancer diagnosis and treatment was 
collected, including information on radiotherapy (RT) dose, 
field, and fractionation schedule and chemotherapy (CT) 
dose per drug. Subsequent CRAs were identified by linkage 
with the population-based Dutch Pathology Registry (PALGA) 
for follow-up years 1990-2014, a unique resource for case 
ascertainment without selection bias from self-reporting. 
Among patients with CRA we also ascertained the occurrence 
of CRC based on cancer registry linkage. 
 
Results: At a median follow-up of 23 years (range: 5-52) since 
childhood cancer diagnosis and a median attained age of 30 
years, we identified 60 patients with at least one 
histologically confirmed CRA, of which 37 had >1 CRA. Most 
common CRA histology was tubular adenoma, followed by 
tubulovillous adenoma. Median age at first CRA diagnosis was 
39 years and median time from childhood cancer diagnosis to 
CRA diagnosis was 28 years. Most CRA patients had been 
treated for leukemia (23.3%) or lymphomas (20.0%). Eight 
CRA patients also developed a CRC. Preliminary univariate 
analyses showed an increased risk of CRA associated with 
abdominal/pelvic RT (odds ratio=2.7; 95% CI: 1.5-4.9). 
 
Conclusion: This study shows a fairly high incidence of 
histologically confirmed CRAs in a relatively young 
population. However, these exploratory analyses need 
further in-depth medical file review to ascertain the 
potential for surveillance bias. More detailed analyses with 
multivariable risk models including RT dose and specific CT 
agents and the role of cancer susceptibility syndromes will be 
presented during the meeting. Also this study provides the 
baseline for a longitudinal assessment of CRA and CRC risk, as 
this population ages. 
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Purpose or Objective: Pediatric cancer treatment, including 
radiotherapy (RT) achieves high cure rates, but can cause 
late health problems. We aim to describe temporal trends of 
pediatric RT use in the Netherlands based on treatment 
experience in the DCOG-LATER cohort of five-yr childhood 
cancer survivors (CCS). 
 
Material and Methods: The Dutch Childhood Oncology Group 
– Late effects after childhood cancer (DCOG-LATER) is a 
collaborative effort of all 7 academic paediatric 
oncology/hematology centres in the Netherlands for optimal 
patient care and research. The DCOG-LATER cohort includes 
6168 five-yr CCS diagnosed 1963-2001 prior to age 18 yrs. 
Most children were treated according to (inter) national 
study protocols. Trained data-managers obtained individual 
medical file information on prior cancer diagnosis and 
treatment including prescribed RT dose, field(s), 
fractionation schedule, machine and RT technique from data 
were coded and stored in a web-based database using study 
coding manuals. Here we summarize trends in RT use by 
calendar period (1963-1979 vs 1980-2001) and diagnosis 
group. 
 
Results: In all, 2426 (39%) CCS received external beam RT 
(EBRT) for a primary tumor or recurrence, most often 
photons, or, <1989, Cobalt-60. Use of orthovoltage and 
electrons was limited. Brachytherapy (2%) and radio isotopes 
(2%) were given, mainly during 1990-2001. RT use decreased 
substantially for all cancer types; most dramatic changes 
were seen among CCS of acute lymphoblastic leukemia, Non-
Hodgkin lymphoma, neuroblastoma, and nephroblastoma, for 
whom RT-use declined from 92%, 79%, 59% and 76% (1963-
1979), to 15%, 8%, 8%, and 27% (1990-2001), respectively, but 
also for bone tumors (75%-32%), retinoblastoma (57%-16%), 
and CNS tumors (82%-47%). Modest declines were seen for 
CCS of Hodgkin lymphoma (74%-50%), soft tissue sarcomas 
(57%-36%), and germ-cell tumors (43%-26%). Among 2094 
leukemia survivors, 773 had any RT, directed to the cranium 
(56%), total body (22%), cranio-spinal axis (12%), and testes 
(4%). Formal trend analyses by childhood cancer type, body 
compartment, and RT dose will be presented. 
 
Conclusion: The use of RT declined over time for all 
pediatric cancer types, likely related to improved diagnostic 
techniques (CT/MRI/pathology) and the introduction of 
multimodal chemotherapy and enhanced surgical techniques. 
Temporal changes in treatment exposures document the 
magnitude of changes, illustrate the heterogeneity of 
treatment exposures and can be correlated with trends in 
health outcomes. 
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Purpose or Objective: To verify the adequacy of dose 
volume constraints in stereotactic radiotherapy and 
radiosurgery of abdominal area considering that dose 
constraints reported in literature are not still validated. This 
study is based on toxicity recorded in organs at risk (OARs) of 
patients enrolled in dose-escalation trials and treated in Our 
Institution. 
 
Material and Methods: Treatment plans of 51 patients (Table 
1) who underwent SBRT (30 patients) or SBRS (21 patients) on 
abdominal neoplasms from March 2007 to May 2014 were 
retrospectively evaluated. All patients were treated using V-
MAT technique. SBRT treatment was delivered in 25-40 Gy in 
5 fractions, and 16-30 Gy in single fraction in SBRS 
treatment. Small intestine and duodenum were the main 
OARs whose irradiation was virtually limited to 30 Gy in SBRT 
treatments and 12 Gy in SBRS treatments. Dosimetric data 
were compared with clinical results in terms of early and late 
toxicity. 
